• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc. (Amendment)

    2/11/22 8:33:34 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LXRX alert in real time by email
    SC 13G/A 1 sc13ga107422lxrx_02142022.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    Lexicon Pharmaceuticals, Inc.

     (Name of Issuer)

    Common Stock, par value $0.001

     (Title of Class of Securities)

    528872302

     (CUSIP Number)

    December 31, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         7,557,501  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              7,557,501  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,557,501  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 528872302

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         7,557,501  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              7,557,501  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,557,501  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.1%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         5,665,077  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              5,665,077  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            5,665,077  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.8%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         5,665,077  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              5,665,077  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            5,665,077  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.8%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         869,596  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              869,596  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            869,596  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    6

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         869,596  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              869,596  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            869,596  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    7

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         13,222,578  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              13,222,578  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            13,222,578  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            8.9%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    8

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         14,360,000  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              14,360,000  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            14,360,000  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.6%  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    9

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         14,360,000  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              14,360,000  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            14,360,000  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.6%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    10

    CUSIP No. 528872302

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         14,360,000  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              14,360,000  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            14,360,000  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.6%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    11

    CUSIP No. 528872302

    Item 1(a).Name of Issuer:

     

    Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    2445 Technology Forest Blvd.

    11th Floor

    The Woodlands, Texas 77381

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

    12

    CUSIP No. 528872302

     

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    528872302

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    13

    CUSIP No. 528872302

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the close of business on December 31, 2021, (i) BVF beneficially owned 7,557,501 Shares, (ii) BVF2 beneficially owned 5,665,077 Shares and (iii) Trading Fund OS beneficially owned 869,596 Shares.

     

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 7,557,501 Shares beneficially owned by BVF.

     

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 5,665,077 Shares beneficially owned by BVF2.

     

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 869,596 Shares beneficially owned by Trading Fund OS.

     

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 13,222,578 Shares beneficially owned in the aggregate by BVF and BVF2.

     

    Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 14,360,000 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the “Partners Managed Account”), including 267,826 Shares held in the Partners Managed Account.

     

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 14,360,000 Shares beneficially owned by Partners.

     

    Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 14,360,000 Shares beneficially owned by BVF Inc.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

     

    (b)Percent of class:

     

    The following percentages are based on 148,895,707 Shares outstanding, which is the total number of Shares outstanding as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2021.

    14

    CUSIP No. 528872302

     

    As of the close of business on December 31, 2021, (i) BVF beneficially owned approximately 5.1% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.8% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.1% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.8% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 8.9% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.6% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned BVF2. Partners, BVF Inc. and Mark Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and the Shares held in the Partners Managed Account.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to the Schedule 13G filed on December 21, 2020.

    15

    CUSIP No. 528872302

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    16

    CUSIP No. 528872302

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 11, 2022

     

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC., its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

       
      Mark N. Lampert    
      President      

     

    17

    Get the next $LXRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LXRX

    DatePrice TargetRatingAnalyst
    3/5/2025$2.00 → $1.00Outperform → Market Perform
    Leerink Partners
    6/17/2024$10.00Buy
    H.C. Wainwright
    4/30/2024$5.00Outperform
    Leerink Partners
    3/7/2023$3.00Hold
    Jefferies
    8/12/2022$10.00Overweight
    Piper Sandler
    More analyst ratings

    $LXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

      Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced details of its "SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)" study were presented on Saturday, May 17. The study design was disclosed in Belgrade, Serbia at one of the premier international heart failure meetings: Heart Failur

      5/19/25 8:00:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

      Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. "We began 2025 delivering on three of our goals for

      5/13/25 4:00:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

      THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000™ program, Lexicon's unique genomics target di

      5/6/25 4:30:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lexicon Appoints Scott Coiante as Chief Financial Officer

      THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019. "I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its

      1/2/25 8:00:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Appoints Ivan H. Cheung to Board of Directors

      THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis

      11/20/24 4:05:47 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

      THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. "I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, includi

      7/8/24 9:15:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lexicon Pharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Lexicon Pharma from Outperform to Market Perform and set a new price target of $1.00 from $2.00 previously

      3/5/25 7:37:06 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target

      H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00

      6/17/24 7:36:12 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Lexicon Pharma with a new price target

      Leerink Partners initiated coverage of Lexicon Pharma with a rating of Outperform and set a new price target of $5.00

      4/30/24 6:26:57 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Financials

    Live finance-specific insights

    See more
    • Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

      Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. "We began 2025 delivering on three of our goals for

      5/13/25 4:00:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast wi

      5/6/25 8:00:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET  THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate milestones and accomplishments.  "In 2024, Lexicon made progress on our Lead to Succeed strategy, resulting in a complete repositioning of the company to focus on advancing our R&D pipe

      3/6/25 4:00:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.

      10-Q - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

      5/14/25 7:08:53 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

      5/13/25 4:03:06 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lexicon Pharmaceuticals Inc.

      SCHEDULE 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      5/12/25 10:36:17 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

      SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      12/9/24 9:33:20 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

      SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      11/14/24 4:26:14 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

      SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      11/12/24 10:32:10 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

      Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

      5/30/23 10:02:49 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      11/17/23 4:55:09 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coats Lonnel bought $10,100 worth of shares (10,000 units at $1.01), increasing direct ownership by 1% to 824,359 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      11/13/23 5:31:49 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Debbane Raymond bought $1,103,957 worth of shares (1,000,000 units at $1.10), increasing direct ownership by 293% to 1,340,847 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      10/12/23 4:01:18 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Swain Judith L converted options into 36,810 shares, increasing direct ownership by 76% to 85,174 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      5/13/25 5:52:13 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sullivan Diane E. converted options into 36,810 shares (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      5/13/25 5:51:31 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sobecki Christopher J converted options into 36,810 shares, increasing direct ownership by 22% to 203,865 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      5/13/25 5:50:50 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care